Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas

Opinion
Video

University of Kansas experts offer guidance for community practitioners treating non-small cell lung cancer (NSCLC).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
Related Content
First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 23rd 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 23rd 2025
Podcast
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Russ Conroy
August 23rd 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
August 23rd 2025
Podcast
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 23rd 2025
Article
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 23rd 2025
Article